TW457234B - β-hydroxylactone derivatives of camptothecin, preparation processes, and anti-tumor pharmaceutical composition thereof - Google Patents

β-hydroxylactone derivatives of camptothecin, preparation processes, and anti-tumor pharmaceutical composition thereof Download PDF

Info

Publication number
TW457234B
TW457234B TW085109645A TW85109645A TW457234B TW 457234 B TW457234 B TW 457234B TW 085109645 A TW085109645 A TW 085109645A TW 85109645 A TW85109645 A TW 85109645A TW 457234 B TW457234 B TW 457234B
Authority
TW
Taiwan
Prior art keywords
ethyl
hydroxy
compound
rmn
dmso
Prior art date
Application number
TW085109645A
Other languages
English (en)
Chinese (zh)
Inventor
Dennis Bigg
Olivier Lavergne
Rodas Francesc Pla
Jacques Pommier
Gerard Ulibarri
Original Assignee
Sod Conseils Rech Applic
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9512670.2A external-priority patent/GB9512670D0/en
Application filed by Sod Conseils Rech Applic filed Critical Sod Conseils Rech Applic
Application granted granted Critical
Publication of TW457234B publication Critical patent/TW457234B/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/22—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains four or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/63—One oxygen atom
    • C07D213/64—One oxygen atom attached in position 2 or 6
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/61—Halogen atoms or nitro radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pyridine Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Cephalosporin Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
TW085109645A 1995-06-21 1996-08-08 β-hydroxylactone derivatives of camptothecin, preparation processes, and anti-tumor pharmaceutical composition thereof TW457234B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9512670.2A GB9512670D0 (en) 1995-06-21 1995-06-21 Camptothecin analogues
US61047696A 1996-03-04 1996-03-04

Publications (1)

Publication Number Publication Date
TW457234B true TW457234B (en) 2001-10-01

Family

ID=26307258

Family Applications (1)

Application Number Title Priority Date Filing Date
TW085109645A TW457234B (en) 1995-06-21 1996-08-08 β-hydroxylactone derivatives of camptothecin, preparation processes, and anti-tumor pharmaceutical composition thereof

Country Status (23)

Country Link
EP (2) EP1251125B1 (da)
JP (2) JP3576171B2 (da)
KR (1) KR100440838B1 (da)
CN (1) CN1114608C (da)
AT (2) ATE312105T1 (da)
AU (1) AU716377B2 (da)
BR (1) BR9608639A (da)
CA (1) CA2225528C (da)
CL (1) CL2004001168A1 (da)
CZ (1) CZ296156B6 (da)
DE (2) DE69635560T2 (da)
DK (2) DK1251125T3 (da)
ES (2) ES2184882T3 (da)
IL (2) IL122635A (da)
MX (1) MX9710228A (da)
NO (1) NO316749B1 (da)
NZ (1) NZ312715A (da)
PL (1) PL185354B1 (da)
PT (1) PT835258E (da)
RO (1) RO117918B1 (da)
RU (1) RU2164515C2 (da)
TW (1) TW457234B (da)
WO (1) WO1997000876A1 (da)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2768431B1 (fr) * 1997-08-29 2000-03-24 Sod Conseils Rech Applic Nouveaux analogues optiquement purs de la camptothecine, nouvel intermediaire de synthese optiquement pur et son procede de preparation
FR2790261B1 (fr) * 1999-02-26 2004-09-10 Sod Conseils Rech Applic Nouveaux analogues optiquement purs de la camptothecine et leurs procedes de preparation
FR2757515B1 (fr) * 1996-12-20 2000-05-05 Sod Conseils Rech Applic Formes prodrogues et nouveaux analogues de la camptothecine, leurs procedes de preparation, leur application comme medicaments et les compositions pharmaceutiques les contenant
FR2757514B1 (fr) * 1996-12-20 1999-02-12 Sod Conseils Rech Applic Nouveaux analogues de la camptothecine, des procedes de preparation, leur application comme medicaments et les compositions pharmaceutiques les contenant
US6559309B2 (en) * 1996-11-01 2003-05-06 Osi Pharmaceuticals, Inc. Preparation of a camptothecin derivative by intramolecular cyclisation
UA57757C2 (uk) * 1996-12-20 2003-07-15 Сос'Єте Де Консей Де Решерш Е Даплікасьон С'Єнтіфік (С.К.Р.А.С.) Аналоги камптотецину, спосіб їх отримання (варіанти) і фармацевтична композиція
FR2772763B1 (fr) * 1997-12-24 2004-01-23 Sod Conseils Rech Applic Nouveaux analogues tetracycliques de camptothecines, leurs procedes de preparation, leur application comme medicaments et les compositions pharmaceutiques les contenant
DE19826499A1 (de) * 1998-06-13 1999-12-16 Beiersdorf Ag Gegen Bakterien, Mycota, Viren, Parasiten und Protozoen wirksame Substanzen
US6207832B1 (en) 1999-04-09 2001-03-27 University Of Pittsburgh Camptothecin analogs and methods of preparation thereof
US6566372B1 (en) 1999-08-27 2003-05-20 Ligand Pharmaceuticals Incorporated Bicyclic androgen and progesterone receptor modulator compounds and methods
MXPA02002032A (es) * 1999-08-27 2003-05-19 Ligand Pharm Inc Compuestos moduladores del receptor de androgeno y metodos.
EP1212322A2 (en) 1999-08-27 2002-06-12 Ligand Pharmaceuticals Incorporated 8-substituted-6-trifluoromethyl-9-pyrido[3,2-g]quinoline compounds as androgen receptor modulators
US6593493B1 (en) 1999-09-14 2003-07-15 Ligand Pharmaceuticals, Inc. RXR modulators with improved pharmacologic profile
FR2801309B1 (fr) * 1999-11-18 2002-01-04 Adir Nouveaux composes analogues de la camptothecine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
DE60124387T2 (de) 2000-02-28 2007-10-11 Pfizer Enterprises Sarl. Synergistische pharmazeutische Zusammensetzungen zur Behandlung von kolorektalem Krebs
US6486320B2 (en) 2000-09-15 2002-11-26 Aventis Pharma S.A. Preparation of camptothecin and of its derivatives
SK5122003A3 (en) 2000-10-27 2003-12-02 Aventis Pharma Sa A combination comprising camptothecin and a stilbene derivative for the treatment of cancer
US6372906B1 (en) 2001-04-12 2002-04-16 University Of Pittsburgh Synthesis of silyl camptothecins and silyl homocamptothecins
FR2825278A1 (fr) * 2001-05-30 2002-12-06 Sod Conseils Rech Applic Produit comprenant du mikanolide, du dihydromikanolide ou un analogue de ceux-ci en association avec un autre agent anti-cancereux pour une utilisation therapeutique dans le traitement du cancer
US6723853B2 (en) 2001-08-27 2004-04-20 University Of Pittsburgh Intermediates and methods of preparation of intermediates in the enantiomeric synthesis of (20R)homocamptothecins and the enantiomeric synthesis of (20R)homocamptothecins
AU2003225642A1 (en) * 2002-03-01 2003-09-16 Fluorous Techonologies Inc Mappicine analogs, intermediates in the synthesis of mappicine analogs and methods of synthesis of mappicine analogs
ITRM20020305A1 (it) * 2002-05-31 2003-12-01 Sigma Tau Ind Farmaceuti Camptotecine con anello lattonico modificato.
ITRM20030344A1 (it) * 2003-07-14 2005-01-15 Ist Naz Stud Cura Dei Tumori 7-n-poliamminoalchil(ossi)imminometilcamptotecine recanti gruppi protettivi.
CN100408582C (zh) * 2004-02-12 2008-08-06 中国人民解放军第二军医大学 高喜树碱类化合物及其制备方法和用途
ITRM20040288A1 (it) * 2004-06-11 2004-09-11 Sigma Tau Ind Farmaceuti Uso della 7-t-butossiimminometilcamptotecina per la preparazione di un medicamento per il trattamento delle neoplasie dell'utero.
WO2006069344A2 (en) 2004-12-22 2006-06-29 Rutgers, The State University Of New Jersey Controlled release hydrogels
CN100339377C (zh) * 2005-09-05 2007-09-26 合肥中科大生物技术有限公司 喜树碱衍生物及其制备
CN1319971C (zh) * 2005-09-09 2007-06-06 合肥中科大生物技术有限公司 喜树碱衍生物及其用途
CN100465175C (zh) * 2005-11-29 2009-03-04 中国人民解放军第二军医大学 7-位取代高喜树碱类化合物及作为药物的用途
CN1319970C (zh) * 2005-12-30 2007-06-06 合肥中科大生物技术有限公司 一种用作抗肿瘤剂的喜树碱衍生物及其制备方法
EP1998809B1 (en) 2006-03-30 2014-06-25 Drais Pharmaceuticals, Inc. Camptothecin-cell penetrating peptide conjugates and pharmaceutical compositions containing the same
WO2007123995A2 (en) * 2006-04-19 2007-11-01 Bionumerik Pharmaceuticals, Inc. Camptothecin-analog with a novel, “flipped” lactone-stable, e-ring and methods for making and using same
CN101220037B (zh) * 2008-01-31 2011-02-16 中国人民解放军第二军医大学 10-位取代高喜树碱类化合物及其用途
CN100592871C (zh) * 2008-03-14 2010-03-03 浙江林学院 一种杀虫剂组合物及其加工方法
CN101979392A (zh) * 2010-09-26 2011-02-23 中国人民解放军第二军医大学 7-芳乙烯基取代高喜树碱类化合物及其作为药物的用途
US20140086975A1 (en) 2010-10-15 2014-03-27 Rutgers, The State University Of New Jersey Hydrogel formulation for dermal and ocular delivery
CN102746314B (zh) * 2011-04-18 2016-07-06 华东师范大学 含有稳定7元内酯环的喜树碱类化合物、制备方法和用途
CN105601641B (zh) * 2015-12-22 2018-01-16 兰州大学 7‑位哌嗪磺酰胺喜树碱类化合物、制备方法及用途
CN106478648B (zh) * 2016-09-21 2018-11-06 桑迪亚医药技术(上海)有限责任公司 一种高喜树碱化合物及其合成方法
CN111777608B (zh) * 2020-07-08 2021-08-03 湖北精瑜材料有限公司 一种新型植物改性喹啉季铵盐化合物和制备方法及应用
AU2022216696A1 (en) * 2021-02-05 2023-08-17 Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Camptothecin compound, preparation method therefor, and application thereof
CN117164601A (zh) * 2022-06-02 2023-12-05 华东师范大学 一种高喜树碱类小分子及其应用
KR20260089547A (ko) * 2023-10-10 2026-06-15 상하이 이노브콩 파마슈티컬 테크놀로지 코., 엘티디 새로운 i형 토포이소머라아제 억제제 및 그 제조 방법과 용도
CN120058721A (zh) * 2024-01-08 2025-05-30 杭州爱科瑞思生物医药有限公司 7-氟烷基取代的喜树碱衍生物的制备及其应用

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5162532A (en) * 1990-12-20 1992-11-10 North Carolina State University Intermediates and method of making camptothecin and camptothecin analogs
US5391745A (en) * 1992-07-23 1995-02-21 Sloan-Kettering Institute For Cancer Research Methods of preparation of camptothecin analogs

Also Published As

Publication number Publication date
HK1056726A1 (en) 2004-02-27
EP1251125B1 (fr) 2005-12-07
DE69623961D1 (de) 2002-10-31
JP3576171B2 (ja) 2004-10-13
ES2254600T3 (es) 2006-06-16
DE69623961T2 (de) 2003-05-08
DE69635560D1 (de) 2006-01-12
RO117918B1 (ro) 2002-09-30
BR9608639A (pt) 1999-06-29
PL185354B1 (pl) 2003-04-30
MX9710228A (es) 1998-03-31
HK1050686A1 (en) 2003-07-04
KR19990028263A (ko) 1999-04-15
DK0835258T3 (da) 2003-02-03
NO975988D0 (no) 1997-12-19
EP0835258A1 (fr) 1998-04-15
CA2225528C (fr) 2007-06-05
NZ312715A (en) 2000-01-28
RU2164515C2 (ru) 2001-03-27
JPH11508249A (ja) 1999-07-21
IL122635A (en) 2001-10-31
PL324339A1 (en) 1998-05-25
IL122635A0 (en) 1998-08-16
IL128044A0 (en) 1999-11-30
EP1251125A3 (fr) 2002-12-11
EP1251125A2 (fr) 2002-10-23
EP0835258B1 (fr) 2002-09-25
CA2225528A1 (fr) 1997-01-09
DE69635560T2 (de) 2006-08-17
AU716377B2 (en) 2000-02-24
CZ415397A3 (cs) 1998-08-12
KR100440838B1 (ko) 2004-12-17
NO975988L (no) 1998-02-19
HK1015783A1 (en) 1999-10-22
WO1997000876A1 (fr) 1997-01-09
PT835258E (pt) 2003-02-28
JP2004123756A (ja) 2004-04-22
CZ296156B6 (cs) 2006-01-11
CN1192740A (zh) 1998-09-09
DK1251125T3 (da) 2006-04-18
ATE224900T1 (de) 2002-10-15
ES2184882T3 (es) 2003-04-16
AU6460896A (en) 1997-01-22
NO316749B1 (no) 2004-04-26
CN1114608C (zh) 2003-07-16
CL2004001168A1 (es) 2005-05-20
ATE312105T1 (de) 2005-12-15

Similar Documents

Publication Publication Date Title
US20210238184A1 (en) Therapeutic compounds
CN105636953B (zh) 1,4‑二取代的哒嗪衍生物及其用于治疗与smn缺乏相关的病症的用途
TWI344466B (en) Novel compounds that are erk inhibitors
JP3576171B2 (ja) カンプトテシンの新規な同族体、その製造方法、その医薬としての用途及びこれを含有する医薬組成物
CN108430998A (zh) 氮杂双环衍生物及其制备方法和用途
JP7420403B2 (ja) キナーゼ阻害剤として使用される化合物およびその応用
JP7190036B2 (ja) 大環状チロシンキナーゼ阻害剤及びその用途
CN109715165A (zh) 巨环激酶抑制剂
TW200911241A (en) Anti-mitotic agent and aurora kinase inhibitor combination as anti-cancer treatment
SG193327A1 (en) Novel imidazo-oxazine compound or salt thereof
CN106986863A (zh) Dna‑pk抑制剂
CN111171049B (zh) 酪氨酸激酶抑制剂及其用途
CN114644627B (zh) AhR抑制剂及其用途
TW410224B (en) Precursory forms and new analogues of camptothecin, the processes for their preparation, their medical application and the pharmaceutical substances that contain them
CA3186769A1 (en) Bicyclic compounds and use thereof
CN103204838A (zh) 多羟基苯并吡喃酮类化合物的合成及其抗肿瘤作用
CN116194452A (zh) 作为Akt激酶抑制剂的化合物
CN104418842B (zh) 取代的吲哚化合物及其使用方法和用途
KR20220140731A (ko) 키나아제 억제제로 작용하는 다환성 화합물
TW202421138A (zh) 哌啶并嘧啶類衍生物、其製備方法及其在醫藥上的應用
CN113149996A (zh) 一种作为cdk9抑制剂的多环酰胺类衍生物、其制备方法及用途
UA63891C2 (en) Camptothecine analogues, method for preparing thereof, intermediate compounds and a pharmaceutical composition containing said camptothecine analogues
CN115785064A (zh) 三取代吡啶衍生物的制备及作为芳香烃受体调节物的应用
CN114181208B (zh) 三并环类AhR抑制剂及其用途
CN110407854A (zh) 新的四环化合物

Legal Events

Date Code Title Description
GD4A Issue of patent certificate for granted invention patent
MM4A Annulment or lapse of patent due to non-payment of fees